Presentation of RP11 Clinical Trial Data at ARVO Conference
Filed with ASX · · 20 pages · English
• PYC is conducting clinical trials of the first investigational drug candidate with disease-modifying potential in a blinding eye disease of childhood called Retinitis Pigmentosa type 11 (RP11) anticipated in 2027 2 • Data from PYC’s ongoing clinical trials in RP11 will be presented by Associate Professor Fred Chen of the Lions Eye Institute in a podium presentation on Sunday 5 May 2024 at the As
PYC Therapeutics Limited on 6ix
In the deck
Earlier from PYC Therapeutics
- RP11 Drug Candidate Progressing to Mid-Stage Human Trials
- Kidney Disease Drug Candidate Progressing to Human Trials
- $74.6 Million Extension of Cash Runway
- PYC Equity Raising to Raise up to $74.6 Million
- RP11 Clinical Trial - Dosing Completed in Cohort 3
Later from PYC Therapeutics
- Successful GLP Tox Studies in Second Blinding Eye Disease
- RP11 Clinical Trial Dosing Completed in Cohort 4
- PMS Drug Candidate Effective In Human Brain Cells
- RP11 Drug Candidate Safe and Well Tolerated
- Commencement of RP11 Multiple Dose Trial
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics